Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Netarsudil vs Latanoprost in Elevated IOP
NCT01731002Phase 2Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Nov 2012
- Primary completion
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of netarsudil in open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Aerie Pharmaceuticals. Primary endpoint: Intraocular Pressure at 28 days. Started Nov 2012; status: completed.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01731002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731002.